InnovAge Holding Q1 2027 earnings

INNV · 2026-11-03 16:07 AMC ET · 8-K on SEC

Revenue and Adjusted EBITDA grew double-digits year-over-year, and the company confirmed its fiscal 2027 guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$264.8M+12.1%—Ex. 99.1, income statement
EPS (GAAP)$0.14+133.3%—Ex. 99.1, income statement
EPS (adjusted)$0.14+133.3%—Ex. 99.1, income statement
Net income$20.9M+172.3%—Ex. 99.1, income statement
Adj. EBITDA$31.3M+77.4%—Ex. 99.1, income statement
Adj. EBITDA margin11.8%+4.3 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
PACE$264.7M+12.3%100%Capitation revenue $264.7M

Margins and costs

  • Gross margin N/A
  • Operating expenses $244.6M (+7.4% YoY)
  • One-offs in the quarter Litigation costs and settlements $0.3M; Offering expenses $1.7M; Loss on assets held for sale $0
  • Effective tax rate 4.0% (prior-year 3.1%)
  • Non-GAAP bridge Adds back interest expense, other investment income, depreciation and amortization, provision for income tax, stock-based compensation, litigation costs and settlements, business optimization, offering expenses, loss on assets held for sale, and gain/loss on sale of assets.

KPIs

MetricActualPrior quarterPrior yearChange
Census8,420—7,890+6.7%
Member months25,070—23,500+6.7%
Cash and cash equivalents$119.3M$97.9M—+21.9%

Guidance

MetricGuidePrior guideChange
Total revenues$1,050M - $1,085M$1,050M - $1,085MUnchanged
Adjusted EBITDA$105M - $115M$105M - $115MUnchanged
Census8,625 - 8,8508,625 - 8,850Unchanged
Total Member Months101,000 - 102,500101,000 - 102,500Unchanged

What drove it

  • Revenue story Total revenues increased approximately 12.1% year-over-year to $264.8 million, driven by capitation revenue of $264.7 million.
  • EPS story Net income attributable to InnovAge increased to $19.6 million, or $0.14 per share, from $8.0 million, or $0.06 per share, in the prior year.
  • One-off check Litigation costs and settlements $0.3M (vs $0.98M prior year); Offering expenses $1.7M (vs $0 prior year); Loss on assets held for sale $0 (vs $0.1M prior year).

The good

  • Adjusted EBITDA margin expanded 4.3 percentage points to 11.8%
  • Center-level Contribution Margin increased 23.8% to $63.6 million

The bad

  • Operating lease assets decreased $1.1 million
  • Accounts receivable decreased $16.9 million

The ugly

  • none

Open questions

  • The company is unable to provide a reconciliation of Adjusted EBITDA guidance to net income (loss).
Full release

InnovAge Holding (INNV) earnings release, November 3, 2026

InnovAge Holding Corp. (INNV) · Form 8-K, Item 2.02 · Filed · SEC filing

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE

FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

DENVER, CO., November 3, 2026

(GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal first quarter ended September 30, 2026.

“We are pleased with our strong stat to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance,” said Patrick Blair, Chief Executive Officer of InnovAge. “Our first quarter results reinforce the progress we have made over the past serval years and our confidence in the long-term potential of the business. As we move forward, we remain focused on strengthening our capabilities, supporting continued growth, and positioning InnovAge to serve more participants over time.”

Financial Results

Fiscal First Quarter 2027 Financial Performance

• Total revenues of $264.8 million, increased approximately 12.1% compared to $236.1 million in the first quarter of fiscal year 2026

• Income Before Income Taxes of $20.0 million increased approximately 153.1%, compared to a Income Before Income Taxes of $7.9 million in the first quarter of fiscal year 2026

• Income Before Income Taxes as a percent of revenue was 7.6%, an increase of 4.2 percentage points, compared to Income Before Income Tax as a percent of revenue of 3.4% in the first quarter of fiscal year 2026

• Center-level Contribution Margin

Financial statements

Income Statement

Three Months Ended September 30, — Financial Results (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Total revenues264,757236,105
Income Before Income Taxes20,0377,916
Net Income20,8787,669
Net Income margin7.9%3.2%
Net Income Attributable to InnovAge Holding Corp.19,5538,019
Net Income per share - basic and diluted0.140.06
Center-level Contribution Margin(1)63,58751,356
Adjusted EBITDA(1)31,25117,642
Adjusted EBITDA margin(1)11.8%7.5%

Income Statement

Based on information as of today, November 3, 2026, InnovAge is confirming the following financial guidance for fiscal year 2027. (in millions)

Low – dollars in millionsHigh – dollars in millions
Census8,6258,850
Total Member Months(1)101,000102,500
Total revenues1,0501,085
Adjusted EBITDA(2)105115

Income Statement

Three Months Ended September 30, — (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA) (UNAUDITED)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Revenues
Capitation revenue264,690235,751
Other service revenue67354
Total revenues264,757236,105
Expenses
External provider costs115,671108,863
Cost of care, excluding depreciation and amortization85,49975,886
Sales and marketing8,6307,605
Corporate, general and administrative29,14930,273
Depreciation and amortization5,6585,085
Loss on assets held for sale104
Total expenses244,607227,816
Operating Income20,1508,289
Other Income (Expense)
Interest expense, net-123-1,251
Other income, net10878
Total other expense-113-373
Income Before Income Taxes20,0377,916
Provision (Benefit) for Income Taxes-841247
Net Income20,8787,669
Less: net income (loss) attributable to noncontrolling interests1,325-350
Net Income Attributable to InnovAge Holding Corp.19,5538,019
Weighted-average number of common shares outstanding - basic136,413,824135,592,487
Weighted-average number of common shares outstanding - diluted137,068,443136,760,874
Net loss per share - basic0.140.06
Net loss per share - diluted0.140.06

Income Statement

Three months ended September 30, — Adjusted EBITDA

Three months ended September 30, – 2026Three months ended September 30, – 2025
Net income20,8787,669
Interest expense, net1231,251
Other investment income(a)-16-499
Depreciation and amortization5,6585,085
Provision (benefit) for income tax-841247
Stock-based compensation1,7412,308
Litigation costs and settlement(b)322979
Business optimization(c)1,707879
Offering expenses(d)1,679
Loss on assets held for sale(e)104
Gain on sale of assets(f)-381
Adjusted EBITDA31,25117,642
Net income (loss) margin7.93.2
Adjusted EBITDA margin11.87.5

Income Statement

Three Months Ended September 30, 2026 — Center-Level Contribution Margin (in thousands)

Three Months Ended September 30, 2026 – PACEThree Months Ended September 30, 2026 – TotalsThree Months Ended September 30, 2026 – TotalsThree Months Ended September 30, 2025 – PACEThree Months Ended September 30, 2025 – All other(a)Three Months Ended September 30, 2025 – TotalsThree Months Ended September 30, 2025 – Totals
Capitation revenue264,690264,690235,751235,751
Other service revenue676797257354
Total revenues264,757264,757235,848257236,105
External provider costs115,671115,671108,863108,863
Cost of care, excluding depreciation and amortization85,49985,49975,73515175,886
Center-Level Contribution Margin63,58763,58751,25010651,356
Sales and marketing8,6307,605
Corporate, general and administrative29,14930,273
Depreciation and amortization5,6585,085
Loss on assets held for sale104
Operating income20,1508,289
Other expense-113-373
Income Before Income Taxes20,0377,916
Loss Before Income Taxes as a percent of revenue7.6%3.4%
Center- Level Contribution Margin as a % of revenue24%21.8%

Balance Sheet

(IN THOUSANDS, EXCEPT NUMBER OF SHARES) (UNAUDITED)

September 30, 2026June 30, 2026
Current Assets
Cash and cash equivalents119,25397,891
Short-term investments43,74043,435
Restricted cash910
Accounts receivable25,49542,390
Prepaid expenses and other34,44427,311
Income tax receivable8433,276
Total current assets223,784214,313
Noncurrent Assets
Property and equipment, net163,689166,086
Operating lease assets20,28921,412
Deposits and other10,10310,318
Goodwill142,046142,046
Other intangible assets, net3,0533,218
Total noncurrent assets339,180343,080
Total assets562,964557,393
Current Liabilities
Accounts payable and accrued expenses100,679115,358
Reported and estimated claims51,42556,864
Due to Medicaid and Medicare27,33418,266

Cash Flow

Three Months Ended September 30, — (IN THOUSANDS) (UNAUDITED)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Operating Activities
Net income20,8787,669
Adjustments to reconcile net income to net cash provided by operating activities
Loss (gain) on disposal of assets5-483
Depreciation and amortization5,6585,085
Operating lease rentals1,5241,562
Loss on assets held for sale104
Amortization of deferred financing costs180213
Stock-based compensation1,7412,308
Deferred income taxes-799247
Other, net927598
Changes in operating assets and liabilities
Accounts receivable16,89513,199
Prepaid expenses and other-7,134-1,306
Income tax receivable2,433
Deposits and other-668-950
Accounts payable and accrued expenses-14,976-24,303
Reported and estimated claims-5,439-368
Due to Medicaid and Medicare9,0681,908
Operating lease liabilities-1,551-1,559
Net cash provided by operating activities28,7423,924
Investing Activities
Purchases of property and equipment-2,988-4,077
Purchases of short-term investments-437-453
Proceeds from sale of assets held for sale3,716
Net cash used in investing activities-3,425-814
Financing Activities
Payments for finance lease obligations-1,404-1,395
Principal payments on long-term debt-634-60,012
Proceeds from the issuance of long-term debt60,082
Payments on financing costs-1,567
Contribution from joint venture partner3,200
Distribution to joint venture partner-361
Taxes paid related to net settlements of stock-based compensation awards-1,557-319
Net cash used in financing activities-3,956-11
Net change in cash, cash equivalents and restricted cash including cash of $0.08 million reclassified to assets held for sale for the three months ended September 30, 202521,3613,099
Less: change in cash and restricted cash reclassified to assets held for sale-82
INCREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH21,3613,017
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD97,90164,140

(1) of $63.6 million, increased 23.8% compared to $51.4 million in the first quarter of fiscal year 2026

• Center-level Contribution Margin

(1) as a percent of revenue was 24.0%, an increase of 2.2 percentage points compared to 21.8% in the first quarter of fiscal year 2026

• Net Income of $20.9 million, compared to Net Income of $7.7 million in the first quarter of fiscal year 2026

• Net Income margin of 7.9%, an increase of 4.6 percentage points, compared to a Net Income margin of 3.2% in the first quarter of fiscal year 2026

• Net Income attributable to InnovAge Holding Corp. of $19.6 million, or earnings per share of $0.14, compared to Net Income attributable to InnovAge Holding Corp. of $8.0 million, or earnings per share of $0.06 in the first quarter of fiscal year 2026

• Adjusted EBITDA

(1) of $31.3 million, an increase of $13.6 million, compared to Adjusted EBITDA of $17.6 million in the first quarter of fiscal year 2026

• Adjusted EBITDA margin

(1) of 11.8%, an increase of 4.3 percentage points, compared to 7.5% in the first quarter of fiscal year 2026

• Census of approximately 8,420 participants compared to 7,890 participants in the first quarter of fiscal year 2026

• Member months of approximately 25,070 compared to 23,500 in first quarter of fiscal year 2026

• Ended the first quarter of fiscal year 2027 with $119.3 million in cash and cash equivalents plus $43.7 million in short-term investments, and $61.4 million in debt on the balance sheet, representing debt under the Company’s senior secured term loan, revolving credit facility and finance lease obligations

(1)

Center-level Contribution Margin and Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” below.

Full Fiscal Year 2027 Financial Guidance

Based on information as of today, November 3, 2026, InnovAge is confirming the following financial guidance for fiscal year 2027.

Expected results and estimates may be impacted by factors outside the Company’s control, and actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor” included herein.

(1)

We define Total Member Months as the total number of participants multiplied by the number of months within the respective reporting period in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year.

(2)

Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of historical Adjusted EBITDA and a reconciliation to net income (loss), the most closely comparable GAAP measure. The Company is unable to provide guidance for net income (loss) or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

Earnings Commentary Approach

With our medium-term margin objectives achieved and InnovAge 3.0 underway, our earnings commentary should also evolve to better reflect the Company’s longer-term operating trajectory. This means, effective this fiscal year 2027 and for the foreseeable future, prepared remarks will emphasize year-over-year performance, which we believe provides a more meaningful measure of underlying progress than the previously-reported sequential-quarter comparisons.

Conference Call

The Company will host a conference call this afternoon at 5:00 PM Eastern Time. A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com... (truncated)be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link ( registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care our participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of September 30, 2026, InnovAge served approximately 8,420 participants across 20 centers in six states. https://www.innovage.com.

Investor Contact:

Ryan Kubota rkubota@innovage.com

Media Contact: press@innovage.com

Forward-Looking Statements - Safe Harbor

This press release and the related conference call may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we may make regarding quarterly or annual guidance; financial outlook, including future revenues and future earnings; mid-term and long-term financial goals; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, build and/or open de novo centers, or to identify and execute tuck-in acquisitions, joint ventures and other strategic partnerships; the expected impact of government policies including rate pressures resulting from Medicaid budget cuts, and the macroeconomic environment; our ability to control costs, mitigate the effects of elevated expenses or reduced healthcare budgets, expand our payer capabilities, execute clinical value and operational value initiatives and strengthen enterprise functions; and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to find suitable geographies for new centers and to attract new participant and retain existing participants in new and existing centers and our ability to obtain licenses to open such centers; (ii) our ability to identify, successfully complete and integrate acquisitions, joint ventures and other strategic partnerships; (iii) the impact of state and federal efforts to reduce healthcare spending, including recent legislation reducing the budget that funds Medicaid; (iv) the impact on our business from ongoing macroeconomic, geopolitical and industry-related challenges, including labor shortages, labor competition, high inflation, and supply chain disruptions, as a result of tariffs and trade disputes; (v) the risk that the cost of providing services under our PACE contracts will exceed our compensation; (vi) our increased costs and expenditures and our inability to execute or realize the benefits of our clinical and operational value initiatives; (vii) the dependence of our revenues upon a limited number of government payors which exposes us to the risk of government funding reductions, legislative changes and federal and state budgetary pressures; (viii) reductions in PACE reimbursement rates; (ix) the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, including our ability to sufficiently cure any deficiencies identified; (x) legal proceedings, enforcement actions and litigation and disputes; (xi) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; and (xii) our ability to adhere to complex and changing government laws and regulations in the healthcare industry.... (truncated)Reports on Form 10-Q and Current Reports on Form 8-K.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Center-level Contribution Margin, Center-level Contribution Margin as a percent of revenue, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. These non-GAAP measures are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to the most directly comparable GAAP measures. We believe that these non-GAAP measures are appropriate measures of operating performance because they allow us to more effectively evaluate our core operating performance and trends from period to period. Our definitions and calculations of non-GAAP measures may vary and not be comparable to similarly titled measures reported by other companies. We believe that these non-GAAP measures help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments and allocating resources, predominantly in the annual budget and forecasting process. For the purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs.

We define Adjusted EBITDA as net income (loss) adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to stock-based compensation, litigation costs and settlement, business optimization, offering expenses, loss on assets held for sale, and loss (gain) on sale of assets. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue.

Schedule 1

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.